Pathogen-mediated NMDA receptor autoimmunity and cellular barrier dysfunction in schizophrenia.

Area of Science:

• Neuroimmunology
• Infectious Disease Immunology
• Psychiatric Research

Background:

• Autoantibodies targeting N-methyl-D-aspartate receptors (NMDAR) are implicated in schizophrenia's cognitive dysfunction.
• Neurotropic pathogens can induce systemic inflammation and barrier defects, potentially triggering autoimmune responses.

Purpose of the Study:

• To investigate the link between Toxoplasma gondii infection, NMDAR autoantibodies, and barrier integrity in schizophrenia.
• To determine if T. gondii exposure and NMDAR antibodies contribute to cognitive impairment in schizophrenia.

Main Methods:

• Utilized mouse models to assess the impact of T. gondii infection on NMDAR antibodies and barrier function (blood-gut, blood-brain).
• Analyzed human cohorts for NMDAR IgG, T. gondii exposure, and barrier permeability markers, comparing schizophrenia patients with controls.
• Assessed cognitive function, specifically delayed memory, in relation to T. gondii and NMDAR antibody seropositivity.

Main Results:

• T. gondii infection in mice led to sustained NMDAR IgG and compromised blood-gut and blood-brain barriers.
• In humans, T. gondii exposure and NMDAR IgG were associated with schizophrenia, independent of medication.
• Schizophrenia patients with combined T. gondii and NMDAR antibody positivity exhibited greater cognitive impairment.

Conclusions:

• T. gondii infection may contribute to schizophrenia pathophysiology through NMDAR autoantibody induction and barrier disruption.
• Identifying NMDAR-related subgroups is crucial for targeted schizophrenia treatments.
• These findings help reconcile conflicting reports on the role of NMDAR autoantibodies in schizophrenia.